Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors

  Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of
  Directors

Business Wire

AUSTIN, Texas -- January 30, 2013

Mirna Therapeutics, a biotechnology company focused on the development and
commercialization of microRNA (miRNA) therapeutics, today announced the
appointment of Clay B. Siegall, Ph.D., co-founder, President, Chief Executive
Officer and Chairman of Board of Directors of Seattle Genetics, as an outside
director to its board of directors.

“We are excited to have Dr. Siegall join our distinguished group of directors,
as his broad pharmaceutical industry experience and achievements in building a
successful oncology company will be invaluable to the Mirna team and our
board, and will help guide Mirna as we continue to advance the development of
microRNA-based therapeutics,” said Dr. Paul Lammers, President and Chief
Executive Officer of Mirna.

“MicroRNA-based therapeutics are an exciting area of cancer research, and
Mirna is well-positioned with a strong pipeline of product candidates,” said
Dr. Siegall. “I am pleased to join the Mirna Board of Directors, given the
company’s early involvement in the miRNA field, and I look forward to working
with the team to advance its promising programs for patients in need.”

Dr. Clay Siegall co-founded Seattle Genetics in 1998 and, under his
leadership, the company has built a diverse pipeline of antibody-based
therapies to address unmet medical needs of cancer patients. Its first
commercial product, ADCETRIS® (brentuximab vedotin) was approved in August
2011 and the company has a broad pipeline of other product candidates. Seattle
Genetics has also entered into multiple strategic collaborations with leading
biotechnology and pharmaceutical companies in oncology. Dr. Siegall has guided
Seattle Genetics’ capital-raising activities, securing more than $675 million
through public and private financings, including the company’s initial public
offering in 2001. He also serves on the Board of Directors of Alder
BioPharmaceuticals, a private biotechnology company. Dr. Siegall was with the
Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and
the National Cancer Institute, National Institutes of Health from 1988 to
1991. He is an author on more than 70 publications and holds 15 patents. Dr.
Siegall received a Ph.D. in Genetics from George Washington University and a
B.S. in Zoology from the University of Maryland.

About microRNAs

miRNAs are approximately 20-25 nucleotides long and affect gene expression by
interacting with messenger RNAs. Unlike siRNAs, miRNAs are encoded in the
human genome and are used as natural regulators of global gene expression.
More than 1,400 miRNAs are encoded in the human genome and comprise
approximately 2% of all mammalian genes. Since each miRNA appears to regulate
the expression of tens to hundreds of different genes, miRNAs can function as
“master-switches,” efficiently regulating and coordinating multiple cellular
pathways and processes. By coordinating the expression of multiple genes,
miRNAs are responsible for guiding proper embryonic development, immunity,
inflammation, as well as cellular growth and proliferation. Misregulation of
miRNAs appears to play a fundamental role in the occurrence, growth and
dissemination of many cancers, and replacement of down regulated miRNAs in
tumor cells results in a positive therapeutic response.

About Mirna Therapeutics

Mirna Therapeutics is a biotechnology company focused on the development and
commercialization of microRNA (miRNA) therapeutics. The Company has a
foundational intellectual property portfolio on the therapeutic use of miRNAs
developed by its own scientists as well as in-licensed from other
institutions. Mirna’s IP portfolio contains >300 miRNAs with applications in
oncology and other diseases. Oncology-directed miRNAs include those that are
key tumor suppressors in cancer, such as miR-34 and let-7 that have proven to
block tumor growth in a number of different pre-clinical animal studies. The
Company, founded in 2007, is located in Austin, Texas, and has received
significant funding from private investors as well as the State of Texas, both
through the State’s Emerging Technology Fund and from the Cancer Prevention
and Research Institute of Texas (CPRIT). For more information, visit
www.mirnarx.com.

Contact:

Mirna Therapeutics, Inc.
Paul Lammers, M.D., M.Sc., 512-901-0900
plammers@mirnarx.com
 
Press spacebar to pause and continue. Press esc to stop.